{"id":"double-stranded-rna-sodium-salt","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Double-stranded RNA (dsRNA) acts as a pathogen-associated molecular pattern (PAMP) that triggers toll-like receptors (TLRs), particularly TLR3, on dendritic cells and other immune cells. This activation promotes the production of type I interferons and pro-inflammatory cytokines, enhancing antitumor immunity and potentially synergizing with checkpoint inhibitors or other immunotherapies.","oneSentence":"Double-stranded RNA activates pattern recognition receptors on immune cells to stimulate innate and adaptive immune responses against tumors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:09:56.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer immunotherapy (specific indications in phase 3 trials not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT05499013","phase":"PHASE1, PHASE2","title":"Study to Assess SLN124 in Patients With Polycythemia Vera","status":"ACTIVE_NOT_RECRUITING","sponsor":"Silence Therapeutics plc","startDate":"2023-01-26","conditions":"Polycythemia Vera","enrollment":69},{"nctId":"NCT05537571","phase":"PHASE2","title":"Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events","status":"COMPLETED","sponsor":"Silence Therapeutics plc","startDate":"2022-12-13","conditions":"Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)","enrollment":180},{"nctId":"NCT06116617","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants","status":"COMPLETED","sponsor":"Sirius Therapeutics Co., Ltd.","startDate":"2024-01-23","conditions":"Thrombosis","enrollment":40},{"nctId":"NCT05722691","phase":"PHASE3","title":"Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2022-06-09","conditions":"COVID-19","enrollment":800},{"nctId":"NCT02918006","phase":"PHASE2","title":"A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine","status":"COMPLETED","sponsor":"Vaxart","startDate":"2016-08-31","conditions":"Influenza","enrollment":179},{"nctId":"NCT00795678","phase":"","title":"Chemotherapeutic Agents in Brain/Breast","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RADAMIN®VIRO"],"phase":"phase_3","status":"active","brandName":"Double-Stranded RNA sodium salt","genericName":"Double-Stranded RNA sodium salt","companyName":"Promomed, LLC","companyId":"promomed-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Double-stranded RNA activates pattern recognition receptors on immune cells to stimulate innate and adaptive immune responses against tumors. Used for Cancer immunotherapy (specific indications in phase 3 trials not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}